Table 1 Association of APOBEC2 expression with the demographic and clinical variables of STAD
Variables | Total(n) | APOBEC2 Negative(n, %) | APOBEC2 Positive(n, %) | P value* |
|---|---|---|---|---|
Age(median,58years) | Â | Â | Â | Â |
≤ 58 | 250 | 81 (32.4) | 169 (67.6) | 0.718 |
> 58 | 246 | 76 (30.9) | 170 (69.1) |  |
Gender | Â | Â | Â | Â |
Male | 355 | 99 (27.9) | 256 (72.1) | 0.004 |
Female | 141 | 58 (41.1) | 83 (58.9) | Â |
Size(median,4.0Â cm) | Â | Â | Â | Â |
≤ 4.0 | 310 | 99 (31.9) | 211 (68.1) | 0.861 |
> 4.0 | 186 | 58 (31.2) | 128 (68.8) |  |
Differential grade | Â | Â | Â | Â |
Well | 7 | 1 (14.3) | 6 (85.7) | < 0.001** |
Moderate | 228 | 26 (11.4) | 202 (88.6) | Â |
Poor | 261 | 130 (49.8) | 131 (50.2) | Â |
WHO histologic type | Â | Â | Â | Â |
Tubular | 319 | 47 (14.7) | 272 (85.3) | < 0.001 |
Papillary | 9 | 1 (11.1) | 8 (88.9) | Â |
Mucinous | 18 | 14 (77.8) | 4 (22.2) | Â |
Poorly cohesive | 150 | 95 (63.3) | 55 (36.7) | Â |
Lauren’s type |  |  |  |  |
Intestinal | 328 | 48 (14.6) | 280 (85.4) | < 0.001 |
Diffuse | 168 | 109 (64.9) | 59 (35.1) | Â |
TNM stage | Â | Â | Â | Â |
I | 160 | 35 (21.9) | 125 (78.1) | 0.003** |
II | 134 | 48 (35.8) | 86 (64.2) | Â |
III | 195 | 70 (35.9) | 125 (64.1) | Â |
IV | 7 | 4 (57.1) | 3 (42.9) | Â |
Chemotherapy | Â | Â | Â | Â |
Yes | 339 | 116 (34.2) | 223 (65.8) | 0.071 |
No | 157 | 41 (26.1) | 116 (73.9) | Â |
Serum CEA (ng/ml) | Â | Â | Â | Â |
< 5 | 384 | 122 (31.8) | 262 (68.2) | 0.833 |
≥ 5 | 81 | 24 (29.6) | 57 (70.4) |  |
Missing | 31 | 11 (35.5) | 20 (64.5) | Â |
Serum CA199(U/ml) | Â | Â | Â | Â |
< 37 | 380 | 120 (31.6) | 260 (68.4) | 0.984 |
≥ 37 | 64 | 20 (31.3) | 44 (68.8) |  |
Missing | 52 | 17 (32.7) | 35 (67.3) | Â |
CD66b(median,21) | Â | Â | Â | Â |
≤ 21 | 255 | 98 (38.4) | 157 (61.6) | 0.001 |
> 21 | 241 | 59 (24.5) | 182 (75.5) |  |
CD163(median,126) | Â | Â | Â | Â |
≤ 126 | 249 | 80 (32.1) | 169 (67.9) | 0.819 |
> 126 | 247 | 77 (31.2) | 170 (68.8) |  |